The term triple-negative breast cancers (TNBC) was first used in 20051 to describe a subset of tumours characterised by absence or low levels of expression of oestrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2). This evidence concerns the gene PGR and triple-negative breast carcinoma.